Arrowhead Pharmaceuticals, Inc. today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the "notes ...
Arrowhead Pharmaceuticals, Inc. today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being ...
News-Medical.Net on MSN
RNA splicing and processing genes emerge as central drivers of aging across tissues
A new research paper featured as the cover of Volume 17, Issue 12 of Aging-US was published on December 22, 2025, titled "A ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
News-Medical.Net on MSN
Understanding sevoflurane-induced neurogenesis inhibition and cognitive dysfunction in children
Every year, millions of infants and children undergo surgery under general anesthesia in the world. Sevoflurane is a commonly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback